Valganciclovir

Generic Name
Valganciclovir
Brand Names
Valcyte
Drug Type
Small Molecule
Chemical Formula
C14H22N6O5
CAS Number
175865-60-8
Unique Ingredient Identifier
GCU97FKN3R
Background

Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.

Indication

Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.

Associated Conditions
Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
Associated Therapies
-
Clinical Trials
Related News

Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

First Posted Date
2012-01-13
Last Posted Date
2018-10-04
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
40
Registration Number
NCT01509404
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

Phase 2
Completed
Conditions
EBV Viremia
CMV Viremia
Interventions
Drug: Placebo
Drug: Valganciclovir
First Posted Date
2011-04-05
Last Posted Date
2019-11-01
Lead Sponsor
University of Minnesota
Target Recruit Count
17
Registration Number
NCT01329185
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Antiviral Treatment of Chronic Lymphocytic Leukemia

Phase 4
Completed
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Valganciclovir
First Posted Date
2010-12-07
Last Posted Date
2015-07-21
Lead Sponsor
Medical University of Vienna
Target Recruit Count
20
Registration Number
NCT01255644
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Completed
Conditions
Anaplastic Large Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma
Noncontiguous Stage II Grade 3 Follicular Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Splenic Marginal Zone Lymphoma
Interventions
Procedure: infection prophylaxis and management
Other: laboratory biomarker analysis
Other: flow cytometry
Genetic: DNA analysis
Genetic: RNA analysis
Procedure: management of therapy complications
Drug: ganciclovir
Drug: valganciclovir
Drug: foscarnet sodium
Procedure: antiviral therapy
Genetic: polymerase chain reaction
Genetic: protein expression analysis
First Posted Date
2010-09-13
Last Posted Date
2019-04-25
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
153
Registration Number
NCT01199562
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

First Posted Date
2010-08-19
Last Posted Date
2012-12-10
Lead Sponsor
Pierrel Research Europe GmbH
Target Recruit Count
212
Registration Number
NCT01185223
Locations
🇦🇹

Pierrel Site 50, Vienna, Austria

🇩🇪

Pierrel Site 12, Berlin, Germany

🇩🇪

Pierrel Site 13, Berlin, Germany

and more 14 locations

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

First Posted Date
2010-01-14
Last Posted Date
2014-06-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT01049633
Locations
🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

First Posted Date
2009-06-10
Last Posted Date
2011-08-01
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
Target Recruit Count
1
Registration Number
NCT00917826
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients

First Posted Date
2009-01-26
Last Posted Date
2012-09-03
Lead Sponsor
Marcus Saemann
Target Recruit Count
40
Registration Number
NCT00828503
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Oral Valganciclovir Versus Valacyclovir

First Posted Date
2007-11-22
Last Posted Date
2012-07-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
46
Registration Number
NCT00562770
Locations
🇺🇸

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Phase 1
Completed
Conditions
Chronic Fatigue Syndrome
First Posted Date
2007-05-24
Last Posted Date
2022-05-27
Lead Sponsor
Stanford University
Target Recruit Count
30
Registration Number
NCT00478465
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy